hotspot -WSS

hotspot

author：knowledge 2025-10-01 21:09:15 - browse：8576

A syringe injects into a segment of DNA — biotech coverage from STAT — Adobe

Two congenitally deaf children can hear for the first time after being treated with gene therapy, according to data presented at a conference Wednesday.

The results are “jaw-droppingly good, just shocking how good. It exceeded the wildest expectations of anybody who started this work,” said Larry Lustig, an otolaryngologist at Columbia University and an investigator on the study.

The new data come from a larger study by Regeneron Pharmaceuticals that will treat nearly two dozen children with a specific type of congenital hearing loss with gene therapy. The clinical trial is meant to measure safety and efficacy of DB-OTO, a gene therapy drug Regeneron is developing to treat children who have hearing loss due to changes in the otoferlin gene. Several teams are targeting this rare form of congenital deafness that affects 1% to 8% of deaf people globally, including a team with Akouos, an Eli Lilly subsidiary, which successfully treated an 11-year-old boy with a similar gene therapy. Lustig calls this the “lowest of the low-hanging fruit” for gene therapy deafness treatments.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Readout Newsletter: New research from Sanofi, Regeneron, etc.

WSS

Cassava reveals details — and problems — with Alzheimer's study

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

Vir antibody drug aimed at influenza A fails in clinical trial

Emergency medicine has repudiated 'excited delirium.' Now what?

Winning ticket for $1 billion Powerball jackpot sold in California

Maker of FluMist seeks to allow at

leisure time

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Affirmative action in medical school literally saved lives

Indian pharmaceutical industry in denial over drug

Supreme Court strikes down use of affirmative action

The FDA weighs the risks of candy

Medicare proposal to cover medical devices draws a mixed reaction

Hospitals struggle to profit from CAR

Medicare proposal to cover medical devices draws a mixed reaction

Ending racial health disparities hinges on penalties, political will

New air purifier tech could be key to improving indoor air quality

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

leisure time

Indian pharmaceutical industry in denial over drug

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Jury awards Florida girl burned by McDonald's Chicken McNugget $800,000 in damages

Stanford president's case begs question: Who takes blame?

I learned firsthand about improving diversity in clinical trials

Vir antibody drug aimed at influenza A fails in clinical trial

Wikipedia

focus

hotspot

hotspot